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STATE-OF-THE-ART PAPER
AND COMMENTARYSTATE-OF-THE-ART PAPER AND COMMENTARYValve Prosthesis–Patient Mismatch (VP–PM): 1978 to 20111123Samuel A. Daneshvar, Shahbudin H. Rahimtoola
1136Philippe Pibarot, Jean G. Dumesnil
Daneshvar and Rahimtoola describe the development of the concept of valve prosthesis-
patient mismatch (VP–PM) in 1978 as well as contemporary issues regarding the diagnosis,
prognosis, and prevention of VP–PM. Among the findings, they conclude that VP–PM can
be accurately identified and predicted with appropriate uses of both the measured and
projected indexed valve effective orifice areas. Severe VP–PM has a significant impact on early
and late mortality, and moderate VP–PM may have a significant effect on mortality in
vulnerable patients. Reference values for various valve types and criteria for diagnosing
VP–PM are reviewed in detail. In an accompanying editorial, Pibarot and Dumesnil, confirm
the importance of understanding and preventing this condition.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY1140Similar Results for Both Patient- and Stent-Related Outcomes for EES and SESLisette Okkels Jensen, Per Thayssen, Evald Høj Christiansen, Hans Henrik Tilsted, Michael Maeng,
Knud Nørregaard Hansen, Anne Kaltoft, Henrik Steen Hansen, Hans Erik Bøtker, Lars Romer Krusell,
Jan Ravkilde, Morten Madsen, Leif Thuesen, Jens Flensted Lassen, for the SORT OUT IV Investigators
In the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical
Outcome IV) trial, which compared a everolimus-eluting stent (EES) with a sirolimus-eluting
stent (SES) in an “all-comer” population, the EES was noninferior to the SES at 9 months
for the composite safety outcome (cardiac death, myocardial infarction [MI], definite stent
thrombosis) and the efficacy outcome (clinically indicated target vessel revascularization). For
this paper, Jensen and colleagues extended the follow-up to 2 years and queried the National
Health System databases for both a patient-related composite endpoint (all death, all MI, or
any revascularization) and a stent-related composite endpoint (cardiac death, target vessel MI,
or symptom-driven target lesion revascularization). At 2 years, there were no differences in
any of the endpoints, but the rate of definite stent thrombosis was lower in the EES group.(continued on page A-26)
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Gupta and colleagues investigated whether the relationship between C-reactive protein (CRP)
and atherosclerosis is modified by body mass index (BMI). CRP and multiple atherosclerosis
phenotypes, including coronary artery calcification (CAC), aortic wall thickness (AWT), and
aortic plaque burden (APB) were measured in subjects from the Dallas Heart Study. Higher
CRP levels were associated with increased CAC prevalence in normal and overweight men
and in normal weight women, but not in obese subjects of either sex. Similarly, the
correlations between CRP, AWT, and APB diminished with increasing BMI, and were
nonsignificant in obese individuals. These results suggest the CRP may not be useful for
atherosclerotic risk prediction in obese individuals.CARDIAC SURGERY1156Contemporary Results for Proximal Aortic Replacement in North AmericaJudson B. Williams, Eric D. Peterson, Yue Zhao, Sean M. O’Brien, Nicholas D. Andersen, D. Craig Miller,
Edward P. Chen, G. Chad Hughes
Williams and colleagues queried the Society of Thoracic Surgeons database for patients
undergoing ascending aortic replacement from 2004 to 2009 to determine contemporary
operative outcomes. Operative mortality was 3.4% for elective and 15.4% for nonelective
cases. The risk of death was nearly 6 times higher after adjustment for emergent compared to
elective surgeries. Among elective patients, end-stage renal disease and reoperative status were
the strongest predictors of mortality. The authors suggest that the low mortality for elective
surgery and the high rate for nonelective surgery may indicate a need to lower the threshold
for elective surgical repair.(continued on page A-27)
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EHEART RHYTHM DISORDERS1163RAD May Improve the Efficacy of PVI for AFEvgeny Pokushalov, Alexander Romanov, Giorgio Corbucci, Sergey Artyomenko, Vera Baranova, Alex Turov,
Natalya Shirokova, Alexander Karaskov, Suneet Mittal, Jonathan S. Steinberg
Pokushalov and colleagues hypothesized that renal artery denervation (RAD) could have a
salutary effect on atrial fibrillation (AF) patterns in patients with poorly controlled
hypertension. In a randomized double-blind study, RAD added to pulmonary vein isolation
(PVI) was compared to PVI and medical therapies in patients with AF and drug-resistant
hypertension. After 1 year, significant reductions in systolic and diastolic blood pressure were
observed in patients treated with RAD and PVI. A total of 69% of subjects treated with PVI
with RAD were AF-free at 12 months compared to only 29% of the patients in the PVI-only
group. These results show that RAD cannot only help to control hypertension, but may
reduce the risk of AF.Editorial Comment: Ralph J. Verdino, p. 1171HEART RHYTHM DISORDERS
1173Chromosome 4q25 Variants Are Genetic Modifiers of Rare
Ion Channel Mutations Associated With Familial AFMarylyn D. Ritchie, Shane Rowan, Gayle Kucera, Tanya Stubblefield, Marcia Blair, Shannon Carter,
Dan M. Roden, Dawood Darbar
Although mutations in ion channels, gap junction proteins, and signaling molecules have been
described for Mendelian forms of atrial fibrillation (AF), penetrance is highly variable. Ritchie
and colleagues tested the hypothesis that 2 common polymorphisms in the chromosome 4q25
region that have been associated with atrial fibrillation (AF) contribute to the
variable penetrance of familial AF. A total of 11 families in which AF was present in 2
ndividuals who also shared a candidate gene mutation in the 4q25 region were analyzed
or mutations in other genes. The presence of common 4q25 risk alleles predicted
hether carriers of rare mutations developed AF.
ditorial Comment: Daniel P. Judge, p. 1182(continued on page A-28)
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Michael Gallagher, Ann DePetris, Judith A. Boura, Ella Kazerooni, Chad Poopat, Mouaz Al-Mallah,
Souheil Saba, Smita Patel, Steven Girard, Thomas Song, David Share, Gilbert Raff
Potential overutilization of coronary computed tomography angiography (CCTA) has
prompted multi-society appropriateness use criteria (AUC). Chinnaiyan and colleagues report
on their use of a continuous quality improvement (CQI) initiative to increase appropriate
utilization of CCTA. Continuous education regarding the AUC for CCTA was provided to
referring physicians during intervention as personal communications and presentations.
Compared to the pre-intervention period, there was a 23% increase in appropriate (A), 60%
decrease in inappropriate (I), 41% decrease in uncertain (U), and 42% decrease in
unclassifiable (UC) scans in the follow-up period. Use of a systematic, educational CQI
program was associated with a significant improvement in the proportion of CCTA
examinations meeting AUC.PULMONARY HYPERTENSION1192Changes in 6MWD Do Not Predict Clinical Events in Patients With PAHGianluigi Savarese, Stefania Paolillo, Pierluigi Costanzo, Carmen D’Amore, Milena Cecere, Teresa Losco,
Francesca Musella, Paola Gargiulo, Caterina Marciano, Pasquale Perrone-Filardi
The 6-min walk distance (6MWD) is a frequently used endpoint in trials of therapies for
pulmonary arterial hypertension (PAH). Savarese and colleagues performed a meta-analysis of
22 trials to determine if changes in 6MWD correlate with clinical outcomes. Active
treatments led to significant reduction of all-cause death, hospitalization for PAH
and/or lung or heart-lung transplantation, and initiation of PAH rescue therapy and a
composite outcome, but no relationship between 6MWD changes and outcomes was
found. While 6MWD has important quality-of-life and prognostic implications, it does
not appear to be a valid surrogate endpoint for the effect of PAH therapies on other
clinical outcomes.Editorial Comment: Stuart Rich, p. 1202
